MetaVia Inc. (MTVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MetaVia Inc. (MTVA) has a cash flow conversion efficiency ratio of -0.469x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.26 Million) by net assets ($9.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MetaVia Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
MetaVia Inc. - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how MetaVia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
MetaVia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MetaVia Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harper Hygienics S.A.
WAR:HRP
|
0.082x |
|
Techno Medical Public Company Limited
BK:TM
|
0.212x |
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
-0.111x |
|
Ely Gold Royalties Inc
V:ELY
|
-0.050x |
|
ATAM VALVES ORD (BSE)
NSE:ATAM
|
0.009x |
|
Urban Logistics Reit PLC
LSE:SHED
|
0.028x |
|
Rostra AG
F:3330
|
N/A |
|
Libero Copper Corp
V:LBC
|
-0.737x |
Annual Cash Flow Conversion Efficiency for MetaVia Inc. (2014–2025)
The table below shows the annual cash flow conversion efficiency of MetaVia Inc. from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see MetaVia Inc. (MTVA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.33 Million | $-15.70 Million | -2.944x | +5.50% |
| 2024-12-31 | $7.93 Million | $-24.71 Million | -3.116x | -381.38% |
| 2023-12-31 | $16.68 Million | $-10.80 Million | -0.647x | -20.19% |
| 2022-12-31 | $21.75 Million | $-11.71 Million | -0.538x | +48.06% |
| 2021-12-31 | $14.60 Million | $-15.13 Million | -1.037x | +30.62% |
| 2020-12-31 | $7.20 Million | $-10.76 Million | -1.494x | -160.96% |
| 2019-12-31 | $12.29 Million | $-7.04 Million | -0.573x | -152.65% |
| 2018-12-31 | $-13.29 Million | $-14.45 Million | 1.088x | +115.93% |
| 2017-12-31 | $3.94 Million | $-26.90 Million | -6.826x | -1175.31% |
| 2016-12-31 | $20.63 Million | $-11.04 Million | -0.535x | -221.96% |
| 2015-12-31 | $-12.38 Million | $-5.43 Million | 0.439x | +19.50% |
| 2014-12-31 | $-531.00K | $-195.00K | 0.367x | -- |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as … Read more